Gallbladder Cancer - Pipeline Review, H1 2018

  • ID: 4540567
  • Report
  • 203 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • Eli Lilly and Co
  • Hutchison MediPharma Ltd
  • Kringle Pharma Inc
  • MedImmune LLC
  • MORE
Gallbladder Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H1 2018, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

This latest pipeline guide Gallbladder Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 17, 5 and 2 respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • Eli Lilly and Co
  • Hutchison MediPharma Ltd
  • Kringle Pharma Inc
  • MedImmune LLC
  • MORE
Introduction

Gallbladder Cancer - Overview

Gallbladder Cancer - Therapeutics Development

Gallbladder Cancer - Therapeutics Assessment

Gallbladder Cancer - Companies Involved in Therapeutics Development

Gallbladder Cancer - Drug Profiles

Gallbladder Cancer - Dormant Projects

Gallbladder Cancer - Discontinued Products

Appendix

List of Tables

Number of Products under Development for Gallbladder Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Gallbladder Cancer - Pipeline by 4SC AG, H1 2018

Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Gallbladder Cancer - Pipeline by Array BioPharma Inc, H1 2018

Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Gallbladder Cancer - Pipeline by Bayer AG, H1 2018

Gallbladder Cancer - Pipeline by BeiGene Ltd, H1 2018

Gallbladder Cancer - Pipeline by Eli Lilly and Co, H1 2018

Gallbladder Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2018

Gallbladder Cancer - Pipeline by Hutchison MediPharma Ltd, H1 2018

Gallbladder Cancer - Pipeline by Ipsen SA, H1 2018

Gallbladder Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Gallbladder Cancer - Pipeline by Kringle Pharma Inc, H1 2018

Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H1 2018

Gallbladder Cancer - Pipeline by MedImmune LLC, H1 2018

Gallbladder Cancer - Pipeline by Molecular Templates Inc, H1 2018

Gallbladder Cancer - Pipeline by Novartis AG, H1 2018

Gallbladder Cancer - Pipeline by NuCana Plc, H1 2018

Gallbladder Cancer - Pipeline by OncoTherapy Science Inc, H1 2018

Gallbladder Cancer - Pipeline by Taris Biomedical LLC, H1 2018

Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H1 2018

Gallbladder Cancer - Dormant Projects, H1 2018

Gallbladder Cancer - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Gallbladder Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4SC AG
  • Advenchen Laboratories LLC
  • Array BioPharma Inc
  • Aslan Pharmaceuticals Pte Ltd
  • Bayer AG
  • BeiGene Ltd
  • Eli Lilly and Co
  • Halozyme Therapeutics Inc
  • Hutchison MediPharma Ltd
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Kringle Pharma Inc
  • Leap Therapeutics Inc
  • MedImmune LLC
  • Molecular Templates Inc
  • Novartis AG
  • NuCana Plc
  • OncoTherapy Science Inc
  • Taris Biomedical LLC
  • VasGene Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll